Keywords: Translational Research | Clinical Utility
Presentation Type: Symposium
Translational research has introduced the potential of using cognitive enhancers to promote the therapeutic learning from cognitive-behavior therapy. Following the success of d-cycloserine for enhancing extinction learning, there has been a general consideration of other agents that may be administered in single doses prior to therapy sessions, in order to enhance the uptake of learning from those sessions. Modafinil is FDA-approved as a wakefulness-promoting agent for disorders such as narcolepsy; it also has a potential as a cognitive enhancer. These cognitive-enhancing effects have been well documented for sleep-deprived individuals, but the magnitude of benefits is less clear when applied outside sleep-deprived samples. In this meta-analytic summary of the literature, we examine the magnitude of benefits for modafinil when applied, in a single dose fashion, as a cognitive enhancer in non-sleep deprived samples. PubMed and PsycINFO databases were used to identify studies published through June 2016. Studies included for analysis were selected if they: (1) investigated modafinil-induced cognitive effects among non-sleep deprived humans; (2) written in English; (3) was placebo-controlled and contained a randomization protocol; and (4) included at least one cognitive test. Studies were excluded if they: (1) included sleep-deprived participants (2) included participants with brain damage and/or a neurological disorder; (2) used modafinil as adjunctive therapy; (3) administered chronic dosing of modafinil; and/or (4) utilized a unique cognitive task. Data from 31 articles, reflecting the assessment of 1,194 participants, were included in this analysis. Preliminary analyses indicate a small to moderate beneficial effect of modafinil broadly across cognitive measures [g = 0.27, 95 % CI (0.027, 0.52), p < .05]. Effect sizes of modafinil on specific cognitive domains suggest stronger effects for executive function and somewhat weaker effects for attention. In this presentation, data regarding dose, population type, and study characteristics will be examined in additional moderator analyses. Implications of findings will be discussed for the potential of modafinil as a strategy for enhancing CBT outcomes.
Friday, November 17
8:30 AM – 10:00 AM
The asset you are trying to access is locked. Please enter your access key to unlock.